Reinventing the discovery, development, and commercialization of new medicines
We develop transformative medicines and technologies by building agile, focused companies called Vants.
successful Phase 3 trials since 2019
subsidiary companies built
Our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.
We employ technology across discovery, development, and commercialization.
Leading innovation in medical dermatology
Advancing potentially transformative therapies for autoimmune diseases
Developing targeted therapies for patients with severe autoimmune disease
Read the latest from Roivant and the media.
Collecting Pharma’s Scraps Can Pay Off for This Biotech
Wall Street Journal
One person’s trash can be another’s treasure. That is essentially the idea behind Roivant ROIV -4.92%decrease; red down pointing triangle, a biotech company with a handful of drugs it got from pharma’s dustbin.
Roivant was founded by the controversial billionaire Vivek Ramaswamy on the premise that large biotech and pharma companies are often too big and complex, creating an opportunity for companies that can focus on a single therapy. The company, which creates a subsidiary “vant” for each new drug it gets, has had both failures and successes, including a notable late-stage flop in Alzheimer’s as well as the $3 billion sale of five of its companies to Japan’s Sumitomo Pharma.
Matt Gline wants you to stop thinking of Roivant as a discard company. In 2023, he'll prove it
Matt Gline has had enough of the quips. Over the course of his seven-year tenure at Roivant Sciences—the last two as CEO—he's fended off what he thinks are condescending characterizations that the “vant” parent company is a discard-reliant pharma and prognostications about the potential of the drugs it works on.
CEO Matt Gline presents on the upcoming year for Roivant at the J.P. Morgan Healthcare Conference in San Francisco, CA
Learn more about our work
Sign up for our latest announcements and upcoming presentations
Advancing medicines that matter
View our broad and differentiated pipeline of investigational drugs.